These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 2469127)
41. Serum prostatic acid phosphatase activity and prostate specific antigen when the prostate gland is enlarged. Jenkins D; Jones RT; Clarke AM Med Lab Sci; 1991 Apr; 48(2):161-3. PubMed ID: 1719330 [TBL] [Abstract][Full Text] [Related]
42. Carcinoma of the prostate. Serum tumour markers. Ekman P Scand J Urol Nephrol Suppl; 1991; 139():15-8. PubMed ID: 1722588 [TBL] [Abstract][Full Text] [Related]
43. [Prostate-specific antigen as a prognostic parameter of treated prostate carcinoma--a reliable tumor marker?]. Knönagel H; Gautschi K; Vonderschmitt DJ; Hauri D Helv Chir Acta; 1988 Jul; 55(3):333-5. PubMed ID: 2459081 [No Abstract] [Full Text] [Related]
44. [Value of the immunohistochemical detection of PSA in the diagnosis of carcinoma of the prostate]. Escaf S; Isorna S; Riesgo I Arch Esp Urol; 1987; 40(9):627-31. PubMed ID: 2449870 [No Abstract] [Full Text] [Related]
45. [The importance of tumor markers in adenocarcinoma of the prostate]. Sampalmieri G; Giancola FL; Cabras A Riv Eur Sci Med Farmacol; 1992; 14(2):139-42. PubMed ID: 1484986 [TBL] [Abstract][Full Text] [Related]
46. [Prostate-specific antigen (PSA) is a valuable marker--if correctly used]. Ekman P Lakartidningen; 1991 Jun; 88(24):2207-8. PubMed ID: 1711643 [No Abstract] [Full Text] [Related]
47. [Isoenzymes of creatine kinase and prostate-specific antigen in the monitoring of prostatic carcinoma]. Scarazatti E; Lino S; Martinoli F; Borroni A Boll Soc Ital Biol Sper; 1990 Jun; 66(6):581-5. PubMed ID: 1701647 [TBL] [Abstract][Full Text] [Related]
48. Study shows PSA better than DRE in screening for prostate cancer. Oncology (Williston Park); 1991 Nov; 5(11):36. PubMed ID: 1722420 [No Abstract] [Full Text] [Related]
49. [Analysis of the serum concentration of prostate-specific antigen as a biological marker in the evolution of disseminated prostatic cancer]. Morote Robles J; de Torres Mateos JA; Soler-Roselló A Actas Urol Esp; 1988; 12(2):152-7. PubMed ID: 2458015 [No Abstract] [Full Text] [Related]
50. [Prostatic specific antigen in the serum in prostatic cancer]. Fuse H; Akakura K; Akimoto S; Shimazaki J Hinyokika Kiyo; 1987 Jul; 33(7):1049-53. PubMed ID: 2446484 [TBL] [Abstract][Full Text] [Related]
52. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance]. Aubert J; Dore B; Irani J; Bon D J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083 [TBL] [Abstract][Full Text] [Related]
53. Ratio of polyclonal-monoclonal prostate-specific antigen levels. Discrimination of nodal status in prostate tumors that produce low marker levels. Stephenson RA; Greskovich FJ; Fritsche HA; James BC Urol Clin North Am; 1991 Aug; 18(3):467-71. PubMed ID: 1715103 [TBL] [Abstract][Full Text] [Related]
54. [Cancer of the prostate: the markers other than prostatic acid phosphatase]. Soula G Bull Cancer; 1985; 72(6):527-30. PubMed ID: 2418900 [TBL] [Abstract][Full Text] [Related]
55. [Value of the serum determination of specific prostatic antigen in the prediction of prostatic cancer]. Morote Robles J; Ruibal Morell A; Pont Salvadó A Actas Urol Esp; 1988; 12(1):10-4. PubMed ID: 2455436 [No Abstract] [Full Text] [Related]
56. Review of acid phosphatase in the diagnosis and prognosis of prostatic cancers. Rubenstein M; Guinan PD; McKiel CF; Dubin A Clin Physiol Biochem; 1988; 6(5):241-52. PubMed ID: 2465864 [TBL] [Abstract][Full Text] [Related]